Diacerein
A slow-acting drug of natural origin that modulates interleukin-1 and promotes cartilage repair. Used in osteoarthritis treatment with anti-inflammatory effects.
Beginner Basics
Plain-English guide to Diacerein
What it does
Diacerein works by reducing inflammation in joints and slowing down cartilage breakdown, which is why researchers study it for joint health and osteoarthritis. It takes several months to show effects but may help reduce joint pain and improve mobility.
Typical dose
Researchers typically use 50 mg taken twice daily by injection under the skin, with therapeutic effects usually appearing after 2-3 months of consistent use.
When to inject
Take with meals to help reduce stomach upset; timing consistency matters more than specific time of day.
Storage
Store the dry powder at room temperature away from light and moisture; once mixed, keep refrigerated and use within the timeframe specified by your supplier.
First-timer tip
This peptide is a slow-burner-don't expect rapid changes. Keep a simple log of any joint sensations or mobility changes over the first 3 months to track progress.
On This Page
Research Status
Clinical trials
For research purposes only. Not approved for human use. Not medical advice.
Research Areas
Side Effects
Occurs in 10-30% of users, typically mild and self-limiting. Usually resolves within 1-2 weeks. Taking diacerein with food significantly reduces incidence. If severe, dose reduction or temporary discontinuation may be needed.
Expected and harmless. Results from the drug's metabolite (rhein) being excreted in urine. No clinical significance; reassure patients this is normal.
Occurs in 5-10% of users. Usually mild and associated with GI upset. Taking with food helps prevent. Discontinue if severe.
Reported in 3-8% of users. Taking with food reduces incidence. Typically resolves with continued use.
Less common than diarrhea but reported in some users. Ensure adequate hydration and fiber intake. May alternate with diarrhea in some patients.
Skin reactions reported in <1% of users. Usually mild and self-resolving. Discontinue if severe or accompanied by systemic symptoms.
Very rare but documented. Elevated liver enzymes reported in <0.1% of users. Monitor liver function tests (ALT, AST) at baseline and periodically during treatment, especially in patients with pre-existing liver disease. Discontinue immediately if jaundice or signs of liver injury develop.
Rare but reported, particularly in patients with pre-existing renal disease. Diacerein is contraindicated in severe renal impairment (creatinine clearance <30 mL/min). Monitor renal function at baseline and periodically.
Dosing Reference
| Parameter | Value |
|---|---|
| Dose range | 50 mg |
Frequency, timing and route - members only | |
Research disclaimer
Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.
Reconstitution Guide
Do not use saline or bacteriostatic saline, use only bacteriostatic water for reconstitution
Do not shake the vial vigorously; gentle swirling prevents peptide degradation
Discard immediately if the solution appears cloudy, discolored, or contains visible particles
Use within 30 days of reconstitution when stored at 2-8°C
Do not freeze the reconstituted solution; freezing may denature the peptide
Use the PeptideVolt reconstitution calculator for your exact concentration
Molecular and Pharmacological Data
Diacerein is a slow-acting drug that inhibits interleukin-1 (IL-1) production and signaling in cartilage and synovial tissues. By suppressing IL-1-mediated inflammation and cartilage-degrading enzyme activity, diacerein reduces joint damage progression and promotes endogenous cartilage repair mechanisms. Its effects develop gradually over weeks to months, making it a disease-modifying osteoarthritis drug (DMOAD) rather than a rapid analgesic.
Track your Diacerein research
Free account. No credit card required.
Recent Research
Insights Into the Ameliorative Effect of Diacerein on Cyclophosphamide-Induced Testicular Toxicity: Targeting TLR4/NF-κB/IL-1β Pathway.
Correction to: Diacerein improves liver fibrosis, steatosis, and atherosclerosis in ApoE knockout mice.
Retraction Note: Diacerein ameliorates amiodarone-induced pulmonary fibrosis via targeting the TGFβ1/α-SMA/Smad3 pathway.
Source: PubMed / NCBI. Updated daily. Articles are listed for research reference only.
Browse the Research Library
40+ peptide profiles with mechanism summaries, dosing data, and reconstitution guides.
View all peptidesResearch Use Only. All content on this page is provided for informational and educational purposes related to scientific research. Diacerein is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.